Literature DB >> 11682157

Wake-promoting and sleep-suppressing actions of hypocretin (orexin): basal forebrain sites of action.

R A España1, B A Baldo, A E Kelley, C W Berridge.   

Abstract

The hypocretins (orexins) are a newly identified peptide family comprised of two peptides, hypocretin-1 and hypocretin-2. Recent observations suggest an involvement of these peptides in the regulation of behavioral state. For example, these peptides are found in a variety of brain regions associated with the regulation of forebrain neuronal and behavioral activity states. Furthermore, when infused into the lateral ventricles in awake animals, hypocretin-1 elicits increased duration of waking beyond that observed in vehicle-treated animals. Previous studies have been limited to an examination of the sleep-wake effects of hypocretin-1 in awake animals. Currently, the sleep-wake effects of hypocretin-2 and the extent to which hypocretins can initiate waking in the sleeping animal remain unclear. To better characterize the wake-promoting actions of the hypocretins, the current studies examined the sleep-wake effects of varying doses (0.007, 0.07 and 0.7 nmol) of hypocretin-1 and hypocretin-2 when administered into sleeping rats (e.g. remote-controlled infusions). Infusions of hypocretin-1 and hypocretin-2 into the lateral ventricles elicited a short latency (0.7 nmol hypocretin-1; 93+/-30 s from the start of the 120-s infusion) increase in electroencephalographic, electromyographic, and behavioral indices of waking. These infusions also produced substantial decreases in slow-wave and rapid-eye movement sleep. Hypocretin-1 was more potent than hypocretin-2 in these actions. Interestingly, hypocretin-1 infused into the fourth ventricle elicited less robust waking which occurred with a longer latency than infusions into the lateral ventricles. These latter observations suggest a forebrain site of action participates in hypocretin-1-induced waking. Within the forebrain, a variety of basal forebrain structures, including the medial preoptic area, the medial septal area and the substantia innominata, receive a moderate hypocretin innervation. Therefore, additional studies examined the sleep-wake effects of bilateral hypocretin-1 infusions into these basal forebrain structures. Robust increases in waking were observed following infusions into, but not outside, the medial septal area, the medial preoptic area and the substantia innominata. These results indicate a potentially prominent role of hypocretins in sleep-wake regulation via actions within certain basal forebrain structures and are consistent with studies indicating a prominent role of hypocretins in sleep/arousal disorders.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11682157     DOI: 10.1016/s0306-4522(01)00319-0

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  99 in total

1.  Neuropharmacology of Sleep and Wakefulness.

Authors:  Christopher J Watson; Helen A Baghdoyan; Ralph Lydic
Journal:  Sleep Med Clin       Date:  2010-12

Review 2.  Hypocretin/orexin involvement in reward and reinforcement.

Authors:  Rodrigo A España
Journal:  Vitam Horm       Date:  2012       Impact factor: 3.421

Review 3.  Energy expenditure: role of orexin.

Authors:  Jennifer A Teske; Vijayakumar Mavanji
Journal:  Vitam Horm       Date:  2012       Impact factor: 3.421

Review 4.  Regulation of cortical acetylcholine release: insights from in vivo microdialysis studies.

Authors:  Jim R Fadel
Journal:  Behav Brain Res       Date:  2010-02-16       Impact factor: 3.332

Review 5.  State-dependent central chemoreception: a role of orexin.

Authors:  Tomoyuki Kuwaki; Aihua Li; Eugene Nattie
Journal:  Respir Physiol Neurobiol       Date:  2010-02-17       Impact factor: 1.931

Review 6.  Orexin receptors: pharmacology and therapeutic opportunities.

Authors:  Thomas E Scammell; Christopher J Winrow
Journal:  Annu Rev Pharmacol Toxicol       Date:  2011       Impact factor: 13.820

7.  Activation of orexin/hypocretin projections to basal forebrain and paraventricular thalamus by acute nicotine.

Authors:  Ravi K Pasumarthi; Jim Fadel
Journal:  Brain Res Bull       Date:  2008-10-23       Impact factor: 4.077

8.  Wake-promoting actions of noradrenergic α1 - and β-receptors within the lateral hypothalamic area.

Authors:  Brooke E Schmeichel; Craig W Berridge
Journal:  Eur J Neurosci       Date:  2012-12-18       Impact factor: 3.386

9.  Dual orexin actions on dorsal raphe and laterodorsal tegmentum neurons: noisy cation current activation and selective enhancement of Ca2+ transients mediated by L-type calcium channels.

Authors:  K A Kohlmeier; S Watanabe; C J Tyler; S Burlet; C S Leonard
Journal:  J Neurophysiol       Date:  2008-07-30       Impact factor: 2.714

10.  The effect of clomipramine on wake/sleep and orexinergic expression in rats.

Authors:  P Feng; Y Hu; D Li; D Vurbic; H Fan; S Wang; K P Strohl
Journal:  J Psychopharmacol       Date:  2008-06-18       Impact factor: 4.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.